摘要
肿瘤坏死因子相关凋亡诱导配体（TRAIL）具有特异性抗肿瘤活性，可通过死亡受体途径及转录因子途径发挥诱导肿瘤细胞凋亡作用。而正常细胞则通过诱骗受体、FLIP及凋亡抑制蛋白来逃逸TRAIL诱导的凋亡。TRAIL与化疗药物、基因治疗联合应用能明显提高肿瘤治疗的靶向性，同时还可以逆转肿瘤细胞对TRAIL的抵抗现象。因此TRAIL作为新型抗肿瘤药物有望应用于临床治疗。
Tumor necrosis factor-related apoptosis inducing ligand （TRAIL） has specific antineoplas- mic activity. TRAIL can induce tumor cells to apoptosis through death receptors pathway and transcription factor pathway, however normal cells can escape induction of TRAIL through decoying receptors Fas-associated death domain protein-like ICE inhibitory proteins and inhibitor of apoptosis. The therapeutic alliance between TRAIL and chemotherapeuties gene therapy can elevate the targeting of oncotherapy, meanwhile can reverse the phenomenon of counteract of tumor cells to TRAIL Therefore, TRAIL may become a new type antitumor drug to clinical treatment.
出处
《国际肿瘤学杂志》
CAS
2009年第2期108-111,共4页
Journal of International Oncology
